Impact of Matrix Metalloproteinase 9 on COPD Development in Polish Patients: Genetic Polymorphism, Protein Level, and Their Relationship with Lung Function

Table 6

Logistic regression analysis for prediction of COPD.

Predictor	Univariable			Multivariable
	P	OR	95% CI	P	OR	95% CI
Gender	<0.0001	8.16	5.73-11.61	0.72	1.22	0.06-26.24
Smoking status	<0.0001	606.04	83.96-4374.76	1.0	-	-
MMP-9 level	<0.0001	1.10	1.06-1.14	0.001	1.12	1.03-1.23
MMP-9/TIMP1 level	0.06	1.00	1.00-1.00
MMP-9/TIMP2 level	0.93	1.00	0.90-1.12
SNP rs3918242	0.34	0.16	0.85-1.59
CNV	0.58	0.81	0.38-1.72

N, number of individuals; COPD, chronic obstructive pulmonary disease groups; CTR, control group; MMP-9, metalloproteinase 9; MMP-9/TIMP1, complex of metalloproteinase 9 and tissue inhibitor of metalloproteinase 1; MMP-9/TIMP2, complex of metalloproteinase 9 and tissue inhibitor of metalloproteinase 2; CNV, copy number variation.